山东新华制药股份(00719.HK)获得米诺地尔搽剂《药品注册证书》

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Minoxidil topical solution, which is intended for the treatment of male pattern baldness and alopecia areata [1] Company Summary - The company submitted the application for the marketing authorization of Minoxidil topical solution to the Center for Drug Evaluation (CDE) in October 2023, which was accepted [1] - The drug registration certificate was granted in August 2025, with the evaluation conclusion being approval for registration [1] Industry Summary - The estimated sales revenue for Minoxidil in public medical institutions in China is approximately RMB 2.36 billion in 2024 [1]